Kenneth J. Pienta

Circulating fibroblast-like cells in men with metastatic prostate cancer.

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial - mesenchymal cell reprogramming and cancer progression.

Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis.

The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor.

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer.

OVOL guides the epithelial-hybrid-mesenchymal transition.

Bone marrow macrophages support prostate cancer growth in bone.

PSMA-Based Detection of Prostate Cancer Bone Lesions With (18)F-DCFPyL PET/CT: A Sensitive Alternative to (99m)Tc-MDP Bone Scan and Na(18)F PET/CT?

Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples.

Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters.

Disseminated tumor cells and dormancy in prostate cancer metastasis.

A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy.

A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cells.

Technical challenges in the isolation and analysis of circulating tumor cells.

Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.

A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow.

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.

Positive Feedback Loops Between Inflammatory, Bone and Cancer Cells During Metastatic Niche Construction.

Correlation of PSMA-Targeted F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.

Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer.

Semiquantitative Parameters in PSMA-Targeted PET Imaging with F-DCFPyL: Variability in Normal-Organ Uptake.

Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells.

The Tumor Microenvironment at a Turning Point Knowledge Gained Over the Last Decade, and Challenges and Opportunities Ahead: A White Paper from the NCI TME Network.

Revisiting Seed and Soil: Examining the Primary Tumor and Cancer Cell Foraging in Metastasis.

The Identification of Macrophage-enriched Glycoproteins Using Glycoproteomics.

The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion.

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

TWIST1-WDR5- Regulates Chromatin to Facilitate Prostate Cancer Metastasis.

Prostate Cancer Local Recurrence Detected With Both F-Fluciclovine and PSMA-targeted F-DCFPyL PET/CT.

Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.

Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer.

Prostate Specific Membrane Antigen Targeted F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT.

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted F-DCFPyL in peripheral ganglia.

Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.

Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Tenascin-C and Integrin α9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment.

Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells.

PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.

Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone.

Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT.

Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests.

Analogous detection of circulating tumor cells using the AccuCyte -CyteFinder system and ISET system in patients with locally advanced and metastatic prostate cancer.

Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.

Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.

PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation.

Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem.

SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework.

A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted F-DCFPyL Positron Emission Tomography Imaging.

Targeting the tumour stroma to improve cancer therapy.

Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.

Cancer as a Social Dysfunction-Why Cancer Research Needs New Thinking.

Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.

Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells.

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays-Reply.

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.

O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis.

Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on F-DCFPyL PET/CT Imaging.

Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification.

Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.

Publisher Correction: 3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification.

Optimization of prostate cancer cell detection using multiplex tyramide signal amplification.

Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

PSMA-targeted [F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework.

Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment.

Recent advances in extracellular vesicle research for urological cancers: From technology to application.

Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.

Novel Structured Reporting Systems for Theranostic Radiotracers.

Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake.

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.

Prospective Evaluation of PSMA-Targeted F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer.

Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.

Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease.

Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance.

Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.

Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.

Prospective Comparison of PET Imaging with PSMA-Targeted F-DCFPyL Versus NaF for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.

Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer.

Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.

Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.

Letter to the Editor re: "Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake".

Uptake of prostate-specific membrane antigen-targeted F-DCFPyL in avascular necrosis of the femoral head.

Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern.

NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma.

CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.

The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer.

Perspectives in Oncology: a new article type for Medical Oncology.

Extracellular vesicle isolation from human renal cancer tissue.

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.

Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion.

Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer.

Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).

A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization.

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.

Prospective evaluation of Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level.

Measurement of PET Quantitative Bias In Vivo.

CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.

Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types.

Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy.

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.

Detection of Early Progression with F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.

Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium.

Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells.

High-Throughput Simultaneous mRNA Profiling Using nCounter Technology Demonstrates That Extracellular Vesicles Contain Different mRNA Transcripts Than Their Parental Prostate Cancer Cells.

Understanding the tumor-immune microenvironment in prostate cancer.

Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).

A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.

Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platforms.

Reply by Authors.

Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer.

Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer.

The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro.

The role of liquid biopsies in prostate cancer management.

Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer.

Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.

Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas.